Etamsylate CAS 2624-44-4 Raw Materials Powder

CAS: 2624-44-4

MF: C10H17NO5S

MW: 263.31

EINECS: 220-090-7

Specification​: 99% min Etamsylate 

Sample: Etamsylate Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Etamsylate Powder Usage and Synthesis.

Etamsylate , also known as Hemostatin, is chemically known as 2,5-dihydroxybenzenesulfonic acid diethylamine salt, 

Etamsylate Powder works by promoting the clotting process. It increases the number of platelets in the blood, enhances their aggregation and adhesion, and promotes the release of clotting substances to accelerate clotting. It is used clinically for the prevention and treatment of excessive surgical bleeding, thrombocytopenic purpura or allergic purpura, and other causes of bleeding. 

Etamsylate CAS 2624-44-4 increases the number of platelets and enhances their aggregation and adhesion, promotes the release of clotting active substances from platelets, shortens clotting time, and accelerates clot contraction. 

Etamsylate Raw Materials is used for the prevention and treatment of bleeding before surgery, and also for intestinal bleeding, cerebral bleeding and Etamsylate Raw Materials is used for the prevention and treatment of bleeding before surgery, and also for intestinal bleeding, cerebral bleeding and urinary tract bleeding.

Application/Function of Etamsylate Powder.

Phenolsulfonamide is indicated for the prevention and treatment of surgical bleeding, thrombocytopenic purpura or allergic purpura, and other causes of bleeding, such as cerebral bleeding, gastrointestinal bleeding, urinary tract bleeding, fundus bleeding, gum bleeding, epistaxis, etc. It can be used in combination with other hemostatic agents such as aminolevulinic acid and vitamin K.

Production Method of Etamsylate Powder

Phenolsulfonamide can increase the number of platelets, enhance their aggregation and adhesion, promote the release of clotting active substances from platelets, shorten the clotting time and accelerate the contraction of blood clots. In addition, it also has the effect of enhancing capillary resistance, reducing its permeability and reducing blood leakage. The hemostatic effect of this product is rapid, with peak effect 1 hour after intravenous injection, and the drug effect can be maintained for 4-6 hours.

• It is easily absorbed orally, and the effect peaks 1 hour after intravenous injection and is maintained for 4-6 hours. It is mainly excreted from the kidney in its original form, and a small amount is excreted from the bile in the feces. Intravenous polymeric plasma expanders should be administered after and not before the use of this product, because dextran, etc., inhibits platelet aggregation and prolongs bleeding and clotting time, which is theoretically antagonistic to this product. It should not be mixed with aminocaproic acid injection to avoid poisoning; it should not be combined with alkaline drugs.
• It can enhance platelet function, reduce capillary permeability, decrease blood exudation and present hemostatic effect. It can also increase the number of platelets in blood, enhance their aggregation and adhesion, promote the release of clotting active substances, shorten the clotting time and accelerate the contraction of blood clots.
• It can increase the number, aggregation and adhesion of platelets and promote the release of clotting active substances from platelets. It also accelerates clot contraction and shortens clotting time, and also enhances capillary resistance and decreases capillary permeability.
• It is used to prevent and treat bleeding before surgery. It is also used for bleeding caused by platelet insufficiency or other causes of bleeding, such as gastrointestinal bleeding, cerebral bleeding and urinary tract bleeding.

Production Method of Etamsylate Powder

The production method of Etamsylate Powder in the market now is benzoquinone method, in which benzoquinone method is to pass sulfur dioxide into the solution of diethylamine, ethanol and water to produce diethylamine sulfite salt first, then add p-benzoquinone into the solution of diethylamine sulfite salt at low temperature, distill under reduced pressure to recover the ethanol after the reaction, and precipitate the crude product after cooling, then add sodium bisulfite and activated carbon to decolorize the water or dilute ethanol to refine the product.

The disadvantages of this process are: the reaction of p-benzoquinone is incomplete, and the solubility of phenolsulfonamide in water and ethanol is large, which makes the product yield low, generally not more than 40%, and the price of p-benzoquinone is high, and there are problems such as the absorption of tail gas when using sulfur dioxide.

Also on the market there is the use of chlorosulfonic acid as a sulfonating agent, sulfonation before making hydroquinone azeotropic dehydration with organic solvents to anhydrous, but this method uses organic solvents, polluting the environment, in which hydrogen chloride gas generated during the sulfonation reaction, polluting the environment.